Kun Peng International Valuation

Is KPEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KPEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KPEA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KPEA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KPEA?

Key metric: As KPEA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KPEA. This is calculated by dividing KPEA's market cap by their current revenue.
What is KPEA's PS Ratio?
PS Ratio	8.8x
Sales	US$4.28m
Market Cap	US$37.52m

KPEA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.8x
Enterprise Value/EBITDA	-43.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does KPEA's PS Ratio compare to its peers?

The above table shows the PS ratio for KPEA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	26.2x
NOTR Nowtransit	49.4x	n/a	US$41.6m
COSM Cosmos Health	0.3x	18.3%	US$16.2m
AHG Akso Health Group	54.8x	n/a	US$141.5m
PDRX PD-Rx Pharmaceuticals	0.3x	n/a	US$5.9m
KPEA Kun Peng International	8.8x	n/a	US$37.5m

Price-To-Sales vs Peers: KPEA is good value based on its Price-To-Sales Ratio (8.8x) compared to the peer average (26.2x).

Price to Sales Ratio vs Industry

How does KPEA's PS Ratio compare vs other companies in the US Healthcare Industry?

30 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$79.34b
CVS CVS Health	0.2x	4.5%	US$74.26b
COR Cencora	0.2x	6.5%	US$48.02b
CNC Centene	0.2x	5.5%	US$30.29b

30 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: KPEA is expensive based on its Price-To-Sales Ratio (8.8x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is KPEA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KPEA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	8.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate KPEA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.93

1.4%

-15.0%

Lantheus Holdings

US$6.2b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

4.4%

28.9%

Sensus Healthcare

US$141.1m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

-3.8%

252.5%